Business
Currency:CNY
2024/H1
Stock NameRevenueRatio
Pharmaceutical product sales3.81B96.44%
Authorization fee income115.93M2.93%
Income from R & D service charges24.95M0.63%
Product
No Data
Region
Currency:CNY
2024/H1
Stock NameRevenueRatio
China3.82B96.65%
United States of America.115.93M2.93%
Other16.3M0.41%